Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 13,000 shares, an increase of 21.5% from the May 31st total of 10,700 shares. Based on an average daily volume of 16,500 shares, the days-to-cover ratio is currently 0.8 days.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Adlai Nortye in a research note on Thursday, June 20th.
Get Our Latest Stock Report on ANL
Adlai Nortye Stock Performance
Hedge Funds Weigh In On Adlai Nortye
An institutional investor recently raised its position in Adlai Nortye stock. Cantor Fitzgerald L. P. boosted its position in Adlai Nortye Ltd. (NASDAQ:ANL – Free Report) by 128.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,310 shares of the company’s stock after acquiring an additional 22,644 shares during the quarter. Cantor Fitzgerald L. P. owned 0.11% of Adlai Nortye worth $362,000 as of its most recent filing with the Securities & Exchange Commission. 35.21% of the stock is currently owned by institutional investors and hedge funds.
Adlai Nortye Company Profile
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Featured Articles
- Five stocks we like better than Adlai Nortye
- Where Do I Find 52-Week Highs and Lows?
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- 3 Fintech Stocks With Good 2021 Prospects
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is the Shanghai Stock Exchange Composite Index?
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.